Early-Stage Hodgkin Lymphoma: New Lessons from an Old Study

Overall survival was improved for patients treated with ABVD chemotherapy versus subtotal nodal irradiation.

A cure rate of ≥90% for patients with early-stage Hodgkin lymphoma (HL) is routinely achieved with current regimens. But this success is tempered by the risk for late-onset morbidity and mortality associated with the initial treatment.

Previously, researchers conducted a multicenter, prospective, randomized, controlled trial to compare the use of 4 to 6 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or 35 Gy subtotal nodal irradiation (STNI) in newly diagnosed patients with nonbulky stage I or II HL (J Clin Oncol 2005; 23:4634). Also, patients with one or more unfavorable clinical features (age ≥40, erythrocyte sedimentation rate ≥50 mm/hour, mixed cellularity or lymphocyte depleted histology, or ≥4 sites of disease) r…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee